Real-world evidence supports decisions when clinical trial data is not enough. Whether for access, value demonstration, or post-approval commitments, it must stand up to scrutiny.
APICES CRO designs RWE programs trusted by regulators, payers, and clinicians.
EmmY Cohort: Long-Term Real-World Evidence in Multiple Myeloma
Real world evidence programs usually sit at the intersection of several functions. Expectations are high, but alignment is often difficult.
We typically work with teams responsible for:
This solution applies when evidence needs to inform real decisions rather than simply exist.
Real-world data is widely available. Usable real-world evidence is not.
In practice, usability depends on:
Without this structure, real-world data creates volume rather than insight.
APICES CRO focus in RWE & HEOR projects is on evidence that can be applied in practice.
That includes:
The objective is evidence that supports action, not just analysis.
Real-world evidence programs benefit from early alignment. We start by clarifying the decision context and intended use of the evidence. From there, study design, data strategy, and analysis plans are defined accordingly.
Execution follows a clear framework, with ongoing alignment across stakeholders as data is collected, analysed, and interpreted.
As a specialized RWE & HEOR CRO, APICES ensures that evidence generation remains tightly aligned with regulatory expectations, payer needs, and real-world decision-making throughout the program lifecycle.
Real-world evidence is often reviewed by audiences with different expectations. This approach is designed to ensure that methodology, data provenance, and analytical choices are explained clearly, whether the audience is regulatory, payer-facing, or internal.
The focus is on consistency, transparency, and traceability from study design through reporting.
Real-world evidence works best when it complements, rather than competes with, clinical trial results. Studies are designed to fill specific gaps, extend insights into routine practice, or support questions that trials are not structured to answer.
This ensures real-world evidence adds value within the broader evidence package.
Clinical value is proven in trials.
Commercial value is proven in health economics.
Talk to our expert, Nathalie Texier. If you are preparing your next early clinical study or want to sanity-check your program’s setup, the next step is a focused conversation.
No packaged answers. Just context, experience, and a clear view on fit.
